Development and evaluation of nanostructured lipid carrier for targeted delivery of gefitinib in breast cancer

Abstract

Breast cancer is the most frequently occurring cancer in women and newlinestands as the second-leading cause of female mortality. Gefitinib is a tyrosine kinase newlineinhibitor (TKI) which inhibits the activity of epidermal growth factor receptor newline(EGFR) in breast cancer.

Description

Keywords

Citation

Collections

item.page.endorsement

item.page.review

item.page.supplemented

item.page.referenced